Last edition
News about "AbbVie"
EU Approves AQUIPTA for Acute Migraine Treatment in Adults
The EC has approved AQUIPTA (atogepant) for the acute treatment and prevention of migraine in adults, based on phase 3 ECLIPSE trial results demonstrating rapid pain relief, sustained efficacy, and consistent benefits across multiple migraine attacks. The approval expands AbbVie’s migraine treatment portfolio across EU.
AbbVie | 03/06/2026 | By News Bureau
US FDA Approves DECNUPAZ for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
AbbVie has received US FDA approval for DECNUPAZ to treat adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), marking the first and only outpatient-initiated ADC for BPDCN and AbbVie’s first approved Antibody Drug Conjugate (ADC) for hematologic malignancies.
AbbVie | 30/05/2026 | By News Bureau
AbbVie Receives Positive CHMP Opinion for MAVIRET in Acute Hepatitis C Treatment
AbbVie receives a positive CHMP opinion for MAVIRET to treat acute hepatitis C, supported by Phase 3 data demonstrating safety and efficacy in adults with acute HCV infection.
AbbVie | 26/05/2026 | By News Bureau | 101
AbbVie Provides US Regulatory Update on TrenibotE BLA
AbbVie gets US FDA Complete Response Letter (CRL) for TrenibotE BLA tied to manufacturing processes; no new clinical studies needed.
AbbVie | 24/04/2026 | By News Bureau | 100
Haisco Signs Exclusive Deal with AbbVie to Develop Novel Pain Therapies
Haisco partners with AbbVie to develop novel pain therapies, with multiple compounds in preclinical to Phase 1 stages targeting pain-related conditions.
AbbVie | 13/04/2026 | By News Bureau | 139
AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.
AbbVie | 19/01/2026 | By News Bureau | 193
AbbVie Aligns Drug Development and Manufacturing Plans for Obesity Portfolio
AbbVie is moving to establish a strong presence in the obesity treatment market, with a strategy that emphasizes manufacturing scalability, supply readiness, and long-term production efficiency alongside clinical development.
AbbVie | 16/01/2026 | By Darshana | 151
AbbVie and RemeGen, a China-based innovative biopharmaceutical company, have entered into an exclusive licensing agreement covering the development, manufacturing, and commercialization of RC148, a novel investigational PD-1/VEGF-targeted bispecific antibody for the treatment of advanced solid tumours.
AbbVie | 13/01/2026 | By Darshana | 157
West Pharmaceutical Services has entered a definitive agreement to divest the manufacturing and supply rights of its SmartDose 3.5mL On-Body Delivery System to AbbVie, as part of a strategic portfolio review, with the transaction expected to close in mid-2026.
AbbVie | 13/01/2026 | By News Bureau | 296
Takeda Becomes a BaseLaunch Partner
BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.
AbbVie | 19/12/2025 | By News Bureau | 129
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy